PhRMA has made numerous statements about the IRA negatively impacting innovation. Learn what the seven primary areas of R&D are that are being targeted for reduction.

Part two discussion where we’ll dive into an example of where Pharma Executives have failed to have, or utilize, a strategic vision for the future.

This is the first of a two-part series on vision that discusses why strategic planning and creating a vision for the future of your company is so important.

National Pharmaceutical Counsel sponsored Spotlight Education Panel Discussion on Oct 2, 2024 with Sarah Edmond, President and CEO.

Coherus BioSciences, Inc. today announced the appointment to its Board of Directors of biopharma commercialization and market access expert Michael Ryan, Pharm. D. Dr. Ryan.

It is advised to use careful consideration of the potential risks and tradeoffs for patients by using a centralized, government-run health technology agency to assess value of new health care interventions.

There is a vital role the biopharmaceutical industry can play in the ongoing debate about health care costs and patient outcomes: developing the rigorous evidence base for policies that impact what patients are experiencing right now.

Reflect on the biopharmaceutical industry's role in solving global health challenges and how to address misunderstandings about brining medicines to market.

The National Pharmaceutical Council (NPC) today announced that Michael L. Ryan, PharmD, Senior Vice President, Worldwide Value, Access, Pricing and Health Economics and Outcomes Research at Bristol Myers Squibb (BMS), has been elected Chair of NPC’s Board of Directors for 2020-2021.